Last summer, Aducanumab was approved by the FDA as a treatment for Alzheimer's disease. The young MultiParker's working group arranged a scientific debate where Dr. Niklas Mattsson-Carlgren and Dr. Ruben Smith, two of MultiPark's senior researchers, discussed the topic.
Watch the recorded version of the debate below.